Dyadic International, Inc. [NASDAQ: DYAI] disclosed that it has inked a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. It has been disclosed by WHO that there are currently fewer than 10 African manufacturers. They have a vaccine production capacity based in 5 countries.
The strategic vision of Rubic is to establish a vaccine research hub and center for higher learning and R&D facilities. Its vision also includes the foundation of a vaccine manufacturing unit with the infrastructure, processing operations. It also includes capabilities for the manufacture and dissemination of high-quality vaccines throughout the African continent.
Furthermore, as per the agreement, Rubic licensed to use the C1 Platform for the research, development, regulatory support, manufacture, launch, marketing, and commercialization of a COVID-19 vaccine(s) that may be man-made in South Africa and sold in multiple countries on the African continent.
Moreover, it also includes that as per the deal Rubic will be accountable for awarding the projected design and funding of Phase II clinical trial within a particular timeframe of the completed technology transfer and licensing agreement.